person · Reporting owner

MAZELSKY JONATHAN JAY

Disclosed activity across 3 companies

Tapewire entity: 33115
SEC CIK: 0001556270

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
DENTSPLY SIRONA Inc.XRAY · Entity 4448	Director	September 30, 2026	October 03, 2026
IDEXX LABORATORIES INC /DEIDXX · Entity 3057	Director · President and CEO	February 26, 2026	March 02, 2026
INSULET CORPPODD · Entity 3516	Director	September 30, 2026	October 03, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

DENTSPLY SIRONA Inc.

Report date September 30, 2026 · Filed October 03, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Phantom Stock (Directors' Deferred Compensation) DDCSEC Table II · derivative / convertible security	Direct	23,345.1175	Reported balance After 2026-09-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-09-30 · Grant · Acquired 3,323.4332 · Balance 23,345.1175 F1: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock following the reporting person's termination of service as a director. F2: Comprised of phantom stock.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock following the reporting person's termination of service as a director.

F2: Comprised of phantom stock.

IDEXX LABORATORIES INC /DE

Report date February 26, 2026 · Filed March 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	83,803.302	Ending reported balance After 2026-02-27 transaction · row 15 15 source rows · reconciled sequence Row 1 · 2026-02-26 · Exercise / conversion · Acquired 23,326 · Balance 106,932.302 Row 2 · 2026-02-26 · Sale · Disposed 1,281 · Balance 105,651.302 F1: Represents the weighted average price of the shares sold ranging from a low of $650.00 to a high of $650.96 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 3 · 2026-02-26 · Sale · Disposed 1,095 · Balance 104,556.302 F2: Represents the weighted average price of the shares sold ranging from a low of $651.06 to a high of $651.85 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 4 · 2026-02-26 · Sale · Disposed 1,669 · Balance 102,887.302 F3: Represents the weighted average price of the shares sold ranging from a low of $652.105 to a high of $653.06 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 5 · 2026-02-26 · Sale · Disposed 1,171 · Balance 101,716.302 F4: Represents the weighted average price of the shares sold ranging from a low of $653.19 to a high of $654.155 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 6 · 2026-02-26 · Sale · Disposed 1,111 · Balance 100,605.302 F5: Represents the weighted average price of the shares sold ranging from a low of $654.24 to a high of $655.2175 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 7 · 2026-02-26 · Sale · Disposed 1,488 · Balance 99,117.302 F6: Represents the weighted average price of the shares sold ranging from a low of $655.275 to a high of $656.205 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 8 · 2026-02-26 · Sale · Disposed 1,343 · Balance 97,774.302 F7: Represents the weighted average price of the shares sold ranging from a low of $656.28 to a high of $657.27 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 9 · 2026-02-26 · Sale · Disposed 2,860 · Balance 94,914.302 F8: Represents the weighted average price of the shares sold ranging from a low of $657.305 to a high of $658.275 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 10 · 2026-02-26 · Sale · Disposed 3,660 · Balance 91,254.302 F9: Represents the weighted average price of the shares sold ranging from a low of $658.30 to a high of $659.24 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 11 · 2026-02-26 · Sale · Disposed 2,859 · Balance 88,395.302 F10: Represents the weighted average price of the shares sold ranging from a low of $659.31 to a high of $660.275 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 12 · 2026-02-26 · Sale · Disposed 1,200 · Balance 87,195.302 F11: Represents the weighted average price of the shares sold ranging from a low of $660.59 to a high of $661.55 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 13 · 2026-02-26 · Sale · Disposed 1,000 · Balance 86,195.302 F12: Represents the weighted average price of the shares sold ranging from a low of $661.65 to a high of $662.55 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 14 · 2026-02-26 · Sale · Disposed 2,589 · Balance 83,606.302 F13: Represents the weighted average price of the shares sold ranging from a low of $662.72 to a high of $663.505 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 15 · 2026-02-27 · Exercise / conversion · Acquired 197 · Balance 83,803.302
Non-Qualified Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $141.60 · Expires 2027-02-13	Direct	0	Reported balance After 2026-02-26 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2026-02-26 · Exercise / conversion · Disposed 23,326 · Balance 0 F14: Grant of option to buy shares of Issuer common stock that vested in five annual installments beginning February 14, 2018.
Incentive Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $505.53 · Expires 2032-02-13	Direct	0	Reported balance After 2026-02-27 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2026-02-27 · Exercise / conversion · Disposed 197 · Balance 0 F15: Grant of option to buy shares of Issuer common stock that vested on February 14, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the weighted average price of the shares sold ranging from a low of $650.00 to a high of $650.96 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F2: Represents the weighted average price of the shares sold ranging from a low of $651.06 to a high of $651.85 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F3: Represents the weighted average price of the shares sold ranging from a low of $652.105 to a high of $653.06 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F4: Represents the weighted average price of the shares sold ranging from a low of $653.19 to a high of $654.155 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F5: Represents the weighted average price of the shares sold ranging from a low of $654.24 to a high of $655.2175 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F6: Represents the weighted average price of the shares sold ranging from a low of $655.275 to a high of $656.205 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F7: Represents the weighted average price of the shares sold ranging from a low of $656.28 to a high of $657.27 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F8: Represents the weighted average price of the shares sold ranging from a low of $657.305 to a high of $658.275 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F9: Represents the weighted average price of the shares sold ranging from a low of $658.30 to a high of $659.24 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F10: Represents the weighted average price of the shares sold ranging from a low of $659.31 to a high of $660.275 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F11: Represents the weighted average price of the shares sold ranging from a low of $660.59 to a high of $661.55 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F12: Represents the weighted average price of the shares sold ranging from a low of $661.65 to a high of $662.55 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F13: Represents the weighted average price of the shares sold ranging from a low of $662.72 to a high of $663.505 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F14: Grant of option to buy shares of Issuer common stock that vested in five annual installments beginning February 14, 2018.

F15: Grant of option to buy shares of Issuer common stock that vested on February 14, 2026.

INSULET CORP

Report date September 30, 2026 · Filed October 03, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,496	Reported balance After 2026-09-30 transaction · row 1 1 source row Row 1 · 2026-09-30 · Grant · Acquired 141 · Balance 1,496 F1: These are deferred common stock units ("Deferred Units") received in lieu of cash compensation pursuant to the Company's Deferred Compensation Plan for Non-Employee Directors. The deferred common stock units will be converted into shares of Company common stock on a one-for-one basis upon distribution, with the value of any fractional shares paid in cash. Distribution of shares of common stock occurs, at the election of the director, either in a lump sum or in substantially equal annual installments pursuant to the Company's Deferred Compensation Plan for Non-Employee Directors.

Filing footnotes · ownership attribution and instrument terms

F1: These are deferred common stock units ("Deferred Units") received in lieu of cash compensation pursuant to the Company's Deferred Compensation Plan for Non-Employee Directors. The deferred common stock units will be converted into shares of Company common stock on a one-for-one basis upon distribution, with the value of any fractional shares paid in cash. Distribution of shares of common stock occurs, at the election of the director, either in a lump sum or in substantially equal annual installments pursuant to the Company's Deferred Compensation Plan for Non-Employee Directors.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 14, 2018 Filed Feb 17, 2018 01:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GrantIncentive Stock Option (right-to-buy) · Derivative	560	Not disclosed Strike: $178.26	Not disclosed	Disclosure SEC source: 0001140361-18-008870 · doc1.xml · derivative · entry 8 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 560 Underlying: Common Stock · 560 shares Expires 2028-02-13 F11 · price: No applicable. F4 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable on the fifth anniversary of the date of grant. Read SEC document
February 14, 2018 Filed Feb 17, 2018 01:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GrantNon-Qualified Stock Option (right-to-buy) · Derivative	25,140	Not disclosed Strike: $178.26	Not disclosed	Disclosure SEC source: 0001140361-18-008870 · doc1.xml · derivative · entry 7 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,140 Underlying: Common Stock · 25,140 shares Expires 2028-02-13 F11 · price: No applicable. F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in five annual installments beginning February 14, 2019. Read SEC document
February 14, 2018 Filed Feb 17, 2018 01:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Tax withholdingCommon Stock	778	$178.26	$138,686.28	Disclosure SEC source: 0001140361-18-008870 · doc1.xml · nonDerivative · entry 6 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,760 F2 · price: Closing price of Issuer's common stock on the NASDAQ market on February 14, 2018. Read SEC document
February 14, 2018 Filed Feb 17, 2018 01:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	459	$0.00	$0.00	Disclosure SEC source: 0001140361-18-008870 · doc1.xml · nonDerivative · entry 5 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,538 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 14, 2018 Filed Feb 17, 2018 01:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	737	$0.00	$0.00	Disclosure SEC source: 0001140361-18-008870 · doc1.xml · nonDerivative · entry 4 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,079 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 14, 2018 Filed Feb 17, 2018 01:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	472	$0.00	$0.00	Disclosure SEC source: 0001140361-18-008870 · doc1.xml · nonDerivative · entry 3 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,342 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 14, 2018 Filed Feb 17, 2018 01:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	403	$0.00	$0.00	Disclosure SEC source: 0001140361-18-008870 · doc1.xml · nonDerivative · entry 2 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,870 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 14, 2018 Filed Feb 17, 2018 01:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	544	$0.00	$0.00	Disclosure SEC source: 0001140361-18-008870 · doc1.xml · nonDerivative · entry 1 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 39 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on December 29, 2017. Read SEC document
December 05, 2017 Filed Dec 7, 2017 22:33 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	961	Not disclosed	Not disclosed	Disclosure SEC source: 0001140361-17-045366 · doc1.xml · derivative · entry 3 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,968 Underlying: Common Stock · 961 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: These restricted stock units were granted to the reporting person on December 5, 2013. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock and vest in five equal annual installments, beginning on the first anniversary date of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015. F3 · price: Not applicable. F2 · derivative.exercise_date: These restricted stock units were granted to the reporting person on December 5, 2013. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock and vest in five equal annual installments, beginning on the first anniversary date of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015. F2 · derivative.expiration_date: These restricted stock units were granted to the reporting person on December 5, 2013. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock and vest in five equal annual installments, beginning on the first anniversary date of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015. Read SEC document
December 05, 2017 Filed Dec 7, 2017 22:33 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Tax withholdingCommon Stock	471	$159.78	$75,256.38	Disclosure SEC source: 0001140361-17-045366 · doc1.xml · nonDerivative · entry 2 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,884 Read SEC document
December 05, 2017 Filed Dec 7, 2017 22:33 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	961	$0.00	$0.00	Disclosure SEC source: 0001140361-17-045366 · doc1.xml · nonDerivative · entry 1 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,355 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 39 shares of common stock acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on September 29, 2017. Read SEC document
September 01, 2017 Filed Sep 6, 2017 22:05 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	2,366	Not disclosed	Not disclosed	Disclosure SEC source: 0001140361-17-034455 · doc1.xml · derivative · entry 3 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,929 Underlying: Common Stock · 2,366 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: These restricted stock units were granted to the reporting person on September 1, 2012. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock and vest in five equal annual installments, beginning on the first anniversary date of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015. F3 · price: Not applicable. F2 · derivative.exercise_date: These restricted stock units were granted to the reporting person on September 1, 2012. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock and vest in five equal annual installments, beginning on the first anniversary date of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015. F2 · derivative.expiration_date: These restricted stock units were granted to the reporting person on September 1, 2012. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock and vest in five equal annual installments, beginning on the first anniversary date of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015. Read SEC document
September 01, 2017 Filed Sep 6, 2017 22:05 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Tax withholdingCommon Stock	1,180	$154.98	$182,876.40	Disclosure SEC source: 0001140361-17-034455 · doc1.xml · nonDerivative · entry 2 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,355 Read SEC document
September 01, 2017 Filed Sep 6, 2017 22:05 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	2,366	$0.00	$0.00	Disclosure SEC source: 0001140361-17-034455 · doc1.xml · nonDerivative · entry 1 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,535 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 86 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 31, 2017 and June 30, 2017. Read SEC document
February 14, 2017 Filed Feb 17, 2017 00:21 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	737	Not disclosed	Not disclosed	Disclosure SEC source: 0001140361-17-008019 · doc1.xml · derivative · entry 12 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,295 Underlying: Common Stock · 737 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2017. F9 · price: Not applicable. F8 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2017. F8 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2017. Read SEC document
February 14, 2017 Filed Feb 17, 2017 00:21 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	472	Not disclosed	Not disclosed	Disclosure SEC source: 0001140361-17-008019 · doc1.xml · derivative · entry 11 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,032 Underlying: Common Stock · 472 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2016 and has been adjusted to reflect the Stock Split. F7 · price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2016 and has been adjusted to reflect the Stock Split. F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2016 and has been adjusted to reflect the Stock Split. F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2016 and has been adjusted to reflect the Stock Split. Read SEC document
February 14, 2017 Filed Feb 17, 2017 00:21 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	403	Not disclosed	Not disclosed	Disclosure SEC source: 0001140361-17-008019 · doc1.xml · derivative · entry 10 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,504 Underlying: Common Stock · 403 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2015 and has been adjusted to reflect the Stock Split. F9 · price: Not applicable. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2015 and has been adjusted to reflect the Stock Split. F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2015 and has been adjusted to reflect the Stock Split. Read SEC document
February 14, 2017 Filed Feb 17, 2017 00:21 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	545	Not disclosed	Not disclosed	Disclosure SEC source: 0001140361-17-008019 · doc1.xml · derivative · entry 9 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,907 Underlying: Common Stock · 545 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2014. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). F9 · price: Not applicable. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2014. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2014. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). Read SEC document
February 14, 2017 Filed Feb 17, 2017 00:21 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GrantRestricted Stock Unit · Derivative	2,295	Not disclosed	Not disclosed	Disclosure SEC source: 0001140361-17-008019 · doc1.xml · derivative · entry 8 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,452 Underlying: Common Stock · 2,295 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2018. F9 · price: Not applicable. F4 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2018. F4 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2018. Read SEC document
February 14, 2017 Filed Feb 17, 2017 00:21 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GrantIncentive Stock Option (right-to-buy) · Derivative	706	Not disclosed Strike: $141.60	Not disclosed	Disclosure SEC source: 0001140361-17-008019 · doc1.xml · derivative · entry 7 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 706 Underlying: Common Stock · 706 shares Expires 2027-02-13 F9 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in five annual installments beginning February 14, 2017. Read SEC document
February 14, 2017 Filed Feb 17, 2017 00:21 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GrantNon-Qualified Stock Option (right-to-buy) · Derivative	23,326	Not disclosed Strike: $141.60	Not disclosed	Disclosure SEC source: 0001140361-17-008019 · doc1.xml · derivative · entry 6 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,326 Underlying: Common Stock · 23,326 shares Expires 2027-02-13 F9 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in five annual installments beginning February 14, 2017. Read SEC document
February 14, 2017 Filed Feb 17, 2017 00:21 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Tax withholdingCommon Stock	719	$141.60	$101,810.40	Disclosure SEC source: 0001140361-17-008019 · doc1.xml · nonDerivative · entry 5 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,083 F2 · price: Closing price of Issuer's common stock on the NASDAQ market on February 14, 2017. Read SEC document
February 14, 2017 Filed Feb 17, 2017 00:21 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	737	$0.00	$0.00	Disclosure SEC source: 0001140361-17-008019 · doc1.xml · nonDerivative · entry 4 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,802 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 14, 2017 Filed Feb 17, 2017 00:21 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	472	$0.00	$0.00	Disclosure SEC source: 0001140361-17-008019 · doc1.xml · nonDerivative · entry 3 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 14, 2017 Filed Feb 17, 2017 00:21 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	403	$0.00	$0.00	Disclosure SEC source: 0001140361-17-008019 · doc1.xml · nonDerivative · entry 2 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,593 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 14, 2017 Filed Feb 17, 2017 00:21 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	545	$0.00	$0.00	Disclosure SEC source: 0001140361-17-008019 · doc1.xml · nonDerivative · entry 1 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,190 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 52 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on December 31, 2016. Read SEC document
December 05, 2016 Filed Dec 7, 2016 21:15 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	962	Not disclosed	Not disclosed	Disclosure SEC source: 0001140361-16-089024 · doc1.xml · derivative · entry 3 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,157 Underlying: Common Stock · 962 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These restricted stock units were granted to the reporting person on December 5, 2013. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock and vest in five equal annual installments, beginning on the first anniversary date of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015. F2 · price: Not applicable. F1 · derivative.exercise_date: These restricted stock units were granted to the reporting person on December 5, 2013. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock and vest in five equal annual installments, beginning on the first anniversary date of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015. F1 · derivative.expiration_date: These restricted stock units were granted to the reporting person on December 5, 2013. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock and vest in five equal annual installments, beginning on the first anniversary date of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015. Read SEC document
December 05, 2016 Filed Dec 7, 2016 21:15 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Tax withholdingCommon Stock	311	$114.10	$35,485.10	Disclosure SEC source: 0001140361-16-089024 · doc1.xml · nonDerivative · entry 2 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,593 Read SEC document
December 05, 2016 Filed Dec 7, 2016 21:15 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	962	$0.00	$0.00	Disclosure SEC source: 0001140361-16-089024 · doc1.xml · nonDerivative · entry 1 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,904 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 18, 2016 Filed Nov 22, 2016 00:33 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative	2,204	Not disclosed Strike: $47.53	Not disclosed	Disclosure SEC source: 0001140361-16-087477 · doc1.xml · derivative · entry 2 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,306 Underlying: Common Stock · 2,204 shares Expires 2019-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy 5,255 shares of IDEXX Laboratories, Inc. common stock that is exercisable in five annual installments of 1,051 shares each beginning on September 1, 2013, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document
November 18, 2016 Filed Nov 22, 2016 00:33 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	2,204	$47.53	$104,756.12	Disclosure SEC source: 0001140361-16-087477 · doc1.xml · nonDerivative · entry 1 MAZELSKY JAY · CIK 0001556270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,942 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 63 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on September 30, 2016. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.